Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib

Published:2014-12-30 Issue:4 Volume:55 Page:392-400
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Suttle A. Benjamin¹,Grossmann Kenneth F.²,Ouellet Daniele¹,Richards-Peterson Lauren E.³,Aktan Gursel³,Gordon Michael S.⁴,LoRusso Patricia M.⁵,Infante Jeffrey R.⁶,Sharma Sunil²,Kendra Kari⁷,Patel Manish⁸,Pant Shubham⁹,Arkenau Hendrik-Tobias¹⁰,Middleton Mark R.¹¹,Blackman Samuel C.¹²,Botbyl Jeff¹³,Carson Stanley W.¹

Affiliation:

1. GlaxoSmithKline; Research Triangle Park; NC USA

2. Huntsman Cancer Institute; University of Utah; Salt Lake City UT USA

3. GlaxoSmithKline; Collegeville; PA USA

4. Pinnacle Oncology Hematology; Scottsdale AZ USA

5. Karmanos Cancer Institute; Wayne State University; Detroit MI USA

6. Sarah Cannon Research Institute/Tennessee Oncology; PLLC; Nashville TN USA

7. Ohio State University; Columbus OH USA

8. Sarah Cannon Research Institute/Florida Cancer Specialists; Sarasota FL USA

9. Sarah Cannon Research Institute/University of Oklahoma; Oklahoma City OK USA

10. Sarah Cannon Research Institute, United Kingdom and University College London; London UK

11. Department of Oncology; National Institute for Health Research Biomedical Research Centre; Oxford UK

12. Juno Therapeutics, Seattle; WA USA

13. Provonix LLC; Mullica Hill; NJ USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference22 articles.

1. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions;King;PLoS One,2013

2. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial;Falchook;Lancet,2012

3. Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates and relationship with its metabolites;Ouellet;J Clin Pharmacol,2014

4. Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation;Bershas;Drug Metabol Dispos,2013

5. The metabolic drug-drug interaction profile of dabrafenib: In vitro investigations and quantitative extrapolation of the P450-mediated DDI risk;Lawrence;Drug Metab Dispos,2014

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitory effect of imperatorin on dabrafenib metabolism in vitro and in vivo;Chemico-Biological Interactions;2024-08

2. Advances in Understanding and Management of Erdheim-Chester Disease;Life Sciences;2024-07

3. A genetic algorithm-based approach for the prediction of metabolic drug-drug interactions involving CYP2C8 or CYP2B6;Journal of Pharmacological and Toxicological Methods;2024-05

4. Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease: Promises and Challenges;Journal of Fungi;2023-04-12

5. A new class of anti-proliferative activity and apoptotic inducer with molecular docking studies for a novel of 1,3-dithiolo[4,5-b]quinoxaline derivatives hybrid with a sulfonamide moiety;RSC Advances;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3